You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽生藥業(06600.HK)「達佑澤」生物製品許可申請獲批
阿思達克 12-08 17:23
賽生藥業(06600.HK)公布,國家藥監局近日已批准公司旗下「達佑澤」(那西妥單抗)的生物製品許可申請,其與粒細胞—巨噬細胞集落刺激因子(GM-CSF)聯合給藥,可用於治療伴有骨或骨髓病變,對既往治療表現為部分緩解、輕微緩解或疾病穩定的1歲及以上兒童或成年復發性或難治性高危神經母細胞瘤患者。 賽生藥業表示,去年9月已在澳門遞交達佑澤的上市申請,並於今年1月根據當地特殊進口政策於台灣地區銷售達佑澤,未來亦將積極尋求擴大使用達佑澤可能解決的疾病適應症。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account